Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on advancing immuno-oncology therapies to overcome tumor-induced immune suppression. Founded in 2006 and headquartered in Burlingame, California, Corvus has built a proprietary platform centered on targeting key immune checkpoints within the adenosine signaling pathway. The company’s research efforts are aimed at enhancing anti-tumor immune responses by developing novel monoclonal antibodies and small molecule antagonists that can be combined with existing cancer therapies.
The company’s lead clinical candidate, CPI-006, is a humanized monoclonal antibody designed to inhibit the activity of CD73, an enzyme expressed on tumor cells that generates immunosuppressive adenosine. By blocking CD73, CPI-006 has demonstrated the ability to promote T-cell activation and inhibit tumor growth in early-stage clinical trials. Corvus is also advancing CPI-818, a selective adenosine A2A receptor antagonist, through preclinical and early clinical development. Both programs are being evaluated as monotherapies and in combination with approved checkpoint inhibitors to maximize anti-tumor efficacy.
Corvus operates its research and development activities primarily in the United States, with collaborations and clinical trial sites spanning North America and Europe. The company leverages partnerships with leading academic institutions and global pharmaceutical firms to accelerate its pipeline. Corvus’s manufacturing strategy includes collaborations with contract development and manufacturing organizations to support the production of antibody and small molecule drug candidates for clinical studies.
Leadership at Corvus is spearheaded by Founder and Chief Executive Officer Peter Ho, PhD, who brings extensive experience in oncology drug discovery and development. The senior management team comprises seasoned professionals in clinical operations, regulatory affairs, and finance, reflecting a deep commitment to advancing novel cancer immunotherapies. Corvus continues to expand its scientific capabilities and corporate infrastructure to support its goal of delivering transformative treatments for patients with difficult-to-treat malignancies.
AI Generated. May Contain Errors.
